Form 4/A for RXRX RECURSION PHARMACEUTICALS, INC.
Accepted 2023-04-28 00:00:00 ET · period of report 2022-02-04 · accession 0001209191-23-026036 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| A | 2023-04-28 | 2022-02-04 | RXRX | Secora Michael | CFO | F - Tax | $11.40 | -678 | 590.4K | -0.1% | -$7,729 |
| MA | 2023-04-28 | 2022-02-04 | RXRX | Secora Michael | CFO | A - Grant | $0.00 | +60.3K | 591.1K | +11% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2022-02-04 | F | D | 678 | $11.40 | 590,380 | D | — | — | (F2) Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 and 609 shares received pursuant to a pro rata distribution from Catalio Nexus Fund II, LP, of which the Reporting Person was a limited partner (the acquisition of such shares from Catalio was inadvertently excluded from the total shares held in the original Form 4 filing and is exempt pursuant to Rule 16a-9). |
| 2 | Common | Class A Common Stock | 2022-02-04 | A | A | 58,342 | $0.00 | 589,101 | D | — | — | (F2) Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 and 609 shares received pursuant to a pro rata distribution from Catalio Nexus Fund II, LP, of which the Reporting Person was a limited partner (the acquisition of such shares from Catalio was inadvertently excluded from the total shares held in the original Form 4 filing and is exempt pursuant to Rule 16a-9). |
| 3 | Common | Class A Common Stock | 2022-02-04 | A | A | 1,957 | $0.00 | 591,058 | D | — | — | (F2) Includes 1,388 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on November 22, 2021 and 609 shares received pursuant to a pro rata distribution from Catalio Nexus Fund II, LP, of which the Reporting Person was a limited partner (the acquisition of such shares from Catalio was inadvertently excluded from the total shares held in the original Form 4 filing and is exempt pursuant to Rule 16a-9). |